DCAF17

Across TCGA pan-cancer cohorts, DCAF17 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated DCAF17 data layer compared with 5 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DCAF17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCAF17 expression acts as an unfavorable survival marker, although some lineages such as LUSC and KIRC show a favorable association.

ACC, MESO, and LGG are the cancer types where DCAF17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.264	0.625	<.001	109	view →
MESO	DFS	Quartile	IV	0.126	0.768	.002	75	view →
LGG	OS	Median	All	0.857	0.931	<.001	39	view →
KIRP	DFS	Quartile	All	0.474	0.771	.002	37	view →
LUSC	DFS	Quartile	All	0.849	0.699	<.001	36	view →
BLCA	DFS	Quartile	All	0.243	0.632	.004	32	view →
KIRC	DFS	Quartile	III,IV	0.790	0.502	.010	20	view →
LUAD	DFS	Tertile	IV	0.769	0.237	.006	18	view →
THCA	OS	Tertile	II,III,IV	0.628	0.896	.007	15	view →
HNSC	DFS	Median	IV	0.400	0.217	.004	15	view →
KICH	DFS	Median	III,IV	0.280	0.910	.001	15	view →
UVM	OS	Median	III,IV	0.296	1.000	.005	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

DCAF17–ACC (DFS)

Open the ACC breakdown →